First half of 2020 results
30/09/2020 – AB Science reports its revenues for the first half of 2020
AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World’s Largest Multiple Sclerosis Research Conference
14/09/2020 – AB Science presents Phase 2B/3 study results in Progressive Multiple Sclerosis at the world’s largest Multiple Sclerosis research conference
AB Science to present results from its AB07015 study in severe asthma at the annual European Respiratory Society International Congress
08/09/2020 – AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congres
AB Science to present results from its AB07002 study
07/09/2020 – AB Science to present results from its Phase 2B/3 AB07002 study in progressive forms of multiple sclerosis at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
AB Science to present results from its AB07002 study in progressive forms of MS at MSVirtual2020
07/09/2020 – AB Science to present results from its Phase 2B/3 AB07002 study in progressive forms of multiple sclerosis at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in vitro
02/09/2020 – New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in-vitro and is a promising candidate for treating COVID-19
Results of the Combined General Shareholders’ Meeting of August 31, 2020
01/09/2020 – AB Science announces the results of the Combined Shareholders’ Meeting of August 31, 2020